SiteOne Therapeutics Secures $100M in Series C Financing to Advance Non-Opioid Pain Treatments

South San Francisco, CA, December 18, 2024 (Business Wire) -- SiteOne Therapeutics has raised $100 million in Series C funding to advance its pipeline of selective ion channel modulators targeting sensory hyperexcitability disorders. The investment will support clinical proof of concept for non-opioid treatments aimed at conditions involving the peripheral nervous system. The company has also appointed key leaders to its Board of Directors to guide its next phase of development.

Read full article here.